Payment overview · 2025
General Payments
$89.09
3 reported records · 2 companies
Healthcare provider profile · identity verified
Mason M. Shives
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GLASGOW, KY · NPI 1699306811
Verified facts
What the public records show
CMS Open Payments records show Mason M. Shives received $89.09 in general payments during 2025 across 3 reported records.
ABBVIE INC. accounted for 59.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.00 | 59.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.09 | 40.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $89.09 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $53.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.09 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.09 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 246 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 208 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 194 | 64 |
| Omeprazole | Omeprazole | 173 | 58 |
| Lisinopril | Lisinopril | 167 | 67 |
| Losartan Potassium | Losartan Potassium | 126 | 49 |
| Buspirone Hcl | Buspirone Hcl | 121 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 78 |
| Prednisone | Prednisone | 112 | 92 |
| Furosemide | Furosemide | 107 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 42 |
| Meloxicam | Meloxicam | 99 | 41 |
| Sertraline Hcl | Sertraline Hcl | 93 | 30 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 92 | 81 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 45 |
| Azithromycin | Azithromycin | 86 | 78 |
| Metformin Hcl | Metformin Hcl | 86 | 33 |
| Montelukast Sodium | Montelukast Sodium | 85 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 30 |
| Jardiance | Empagliflozin | 70 | 18 |
| Potassium Chloride | Potassium Chloride | 69 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 26 |
| Ozempic | Semaglutide | 65 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 24 |
| Simvastatin | Simvastatin | 64 | 17 |
| Trazodone Hcl | Trazodone Hcl | 63 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 21 |
| Metformin Hcl Er | Metformin Hcl | 58 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 29 |
| Ondansetron Odt | Ondansetron | 54 | 40 |
| Bupropion Xl | Bupropion Hcl | 53 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 21 |
| Fluconazole | Fluconazole | 48 | 42 |
| Trulicity | Dulaglutide | 48 | 12 |
| Allopurinol | Allopurinol | 47 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 43 |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 22 |
| Glipizide Er | Glipizide | 45 | 19 |
| Gabapentin | Gabapentin | 44 | 22 |
| Dexamethasone | Dexamethasone | 42 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Famotidine | Famotidine | 40 | 24 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | 14 |
| Eliquis | Apixaban | 37 | 14 |
| Nystatin | Nystatin | 37 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 12 |
| Carvedilol | Carvedilol | 36 | 12 |
| Cephalexin | Cephalexin | 36 | 29 |
| Clonidine Hcl | Clonidine Hcl | 35 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 12 |
| Glipizide | Glipizide | 32 | 12 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 27 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 12 |
| Ibuprofen | Ibuprofen | 30 | 18 |
| Linzess | Linaclotide | 28 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Atenolol | Atenolol | 25 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 14 |
| Glimepiride | Glimepiride | 20 | 11 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | 11 |
| Levofloxacin | Levofloxacin | 18 | 18 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | 14 |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 15 |
| Valsartan | Valsartan | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 13 |
| Alprazolam | Alprazolam | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $89.09 · 3 records | ABBVIE INC. | Ozempic, Rybelsus, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error